Literature DB >> 27293521

Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies.

Johnathan Zhang1, Douglas Nguyen2, Ke-Qin Hu1.   

Abstract

Chronic Hepatitis C virus (HCV) infection carries a significant clinical burden in the United States, affecting more than 4.6 million Americans. Untreated chronic HCV infection can result in cirrhosis, portal hypertension, and hepatocellular carcinoma. Previous interferon based treatment carried low rates of success and significant adverse effects. The advent of new generation oral antiviral therapy has led to major improvements in efficacy and tolerability but has also resulted in an explosion of data with increased treatment choice complexity. Treatment guidelines are constantly evolving due to emerging regimens and real world treatment data. There also still remain subpopulations for whom current treatments are lacking or unclearly defined. Thus, the race for development of HCV treatment regimens still continues. This review of the current literature will discuss the current recommended treatment strategies and briefly overview next generation agents.

Entities:  

Keywords:  Direct Antiviral Agents (DAA); HCV infection; HCV treatment; Hepatitis C

Year:  2016        PMID: 27293521      PMCID: PMC4897966     

Source DB:  PubMed          Journal:  N Am J Med Sci (Boston)        ISSN: 1946-9357


  37 in total

1.  Toward a more accurate estimate of the prevalence of hepatitis C in the United States.

Authors:  Brian R Edlin; Benjamin J Eckhardt; Marla A Shu; Scott D Holmberg; Tracy Swan
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

2.  Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.

Authors:  Jordan J Feld; Christophe Moreno; Roger Trinh; Edward Tam; Stefan Bourgeois; Yves Horsmans; Magdy Elkhashab; David E Bernstein; Ziad Younes; Robert W Reindollar; Lois Larsen; Bo Fu; Kevin Howieson; Akshanth R Polepally; Andreas Pangerl; Nancy S Shulman; Fred Poordad
Journal:  J Hepatol       Date:  2015-10-22       Impact factor: 25.083

3.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Authors:  Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

4.  Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

Authors:  Marc Bourlière; Jean-Pierre Bronowicki; Victor de Ledinghen; Christophe Hézode; Fabien Zoulim; Philippe Mathurin; Albert Tran; Dominique G Larrey; Vlad Ratziu; Laurent Alric; Robert H Hyland; Deyuan Jiang; Brian Doehle; Phillip S Pang; William T Symonds; G Mani Subramanian; John G McHutchison; Patrick Marcellin; François Habersetzer; Dominique Guyader; Jean-Didier Grangé; Véronique Loustaud-Ratti; Lawrence Serfaty; Sophie Metivier; Vincent Leroy; Armand Abergel; Stanislas Pol
Journal:  Lancet Infect Dis       Date:  2015-03-13       Impact factor: 25.071

Review 5.  Management of hepatitis C infection before and after liver transplantation.

Authors:  Stefano Fagiuoli; Roberto Ravasio; Maria Grazia Lucà; Anna Baldan; Silvia Pecere; Alessandro Vitale; Luisa Pasulo
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

6.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

7.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

8.  Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

Authors:  Stefan Zeuzem; Reem Ghalib; K Rajender Reddy; Paul J Pockros; Ziv Ben Ari; Yue Zhao; Deborah D Brown; Shuyan Wan; Mark J DiNubile; Bach-Yen Nguyen; Michael N Robertson; Janice Wahl; Eliav Barr; Joan R Butterton
Journal:  Ann Intern Med       Date:  2015-07-07       Impact factor: 51.598

9.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Authors:  Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

10.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

View more
  20 in total

1.  Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.

Authors:  Santa Olivera; Angel Perez; Viviana Falcon; Dioslaida Urquiza; Dagmara Pichardo; Gillian Martinez-Donato
Journal:  Arch Virol       Date:  2020-02-03       Impact factor: 2.574

2.  A Descriptive Analysis of a Community Clinic Providing Hepatitis C Treatment to Poor and Uninsured Patients.

Authors:  Omar T Sims; Pamela A Melton; Shaonin Ji
Journal:  J Community Health       Date:  2018-08

3.  Improving Metabolic Stability with Deuterium: The Discovery of BMT-052, a Pan-genotypic HCV NS5B Polymerase Inhibitor.

Authors:  Kyle Parcella; Kyle Eastman; Kap-Sun Yeung; Katharine A Grant-Young; Juliang Zhu; Tao Wang; Zhongxing Zhang; Zhiwei Yin; Dawn Parker; Kathy Mosure; Hua Fang; Ying-Kai Wang; Julie Lemm; Xiaoliang Zhuo; Umesh Hanumegowda; Mengping Liu; Karen Rigat; Maria Donoso; Maria Tuttle; Tatyana Zvyaga; Zuzana Haarhoff; Nicholas A Meanwell; Matthew G Soars; Susan B Roberts; John F Kadow
Journal:  ACS Med Chem Lett       Date:  2017-06-29       Impact factor: 4.345

Review 4.  Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.

Authors:  Zaina T Al-Salama; Emma D Deeks
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

5.  Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world.

Authors:  Moisés Uriarte-Pinto; Herminia Navarro-Aznarez; Natalia De La Llama-Celis; Piedad Arazo-Garcés; Ana María Martínez-Sapiña; María Reyes Abad-Sazatornil
Journal:  Int J Clin Pharm       Date:  2018-03-20

6.  Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.

Authors:  Tanvi Khera; Daniel Todt; Koen Vercauteren; C Patrick McClure; Lieven Verhoye; Ali Farhoudi; Sabin Bhuju; Robert Geffers; Thomas F Baumert; Eike Steinmann; Philip Meuleman; Thomas Pietschmann; Richard J P Brown
Journal:  Antiviral Res       Date:  2017-01-03       Impact factor: 10.103

Review 7.  Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.

Authors:  Sarah L Greig
Journal:  Drugs       Date:  2016-10       Impact factor: 11.431

8.  Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions.

Authors:  Romy Weller; Kathrin Hueging; Richard J P Brown; Daniel Todt; Sebastian Joecks; Florian W R Vondran; Thomas Pietschmann
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

Review 9.  Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.

Authors:  Matteo Pirro; Vanessa Bianconi; Daniela Francisci; Elisabetta Schiaroli; Francesco Bagaglia; Amirhossein Sahebkar; Franco Baldelli
Journal:  J Cell Mol Med       Date:  2017-07-18       Impact factor: 5.310

10.  Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience.

Authors:  Gianfranco Lauletta; Sabino Russi; Fabio Pavone; Angelo Vacca; Franco Dammacco
Journal:  Arthritis Res Ther       Date:  2017-04-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.